Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
BACKGROUND
Translation of preclinical studies into effective human cancer therapy is hampered by the lack of defined molecular expression patterns in mouse models that correspond to the human counterpart. We sought to generate an open source TRAMP mouse microarray dataset and to use this array to identify differentially expressed genes from human prostate cancer (PCa) that have concordant expression in TRAMP tumors, and thereby represent lead targets for preclinical therapy development.


METHODS
We performed microarrays on total RNA extracted and amplified from eight TRAMP tumors and nine normal prostates. A subset of differentially expressed genes was validated by QRT-PCR. Differentially expressed TRAMP genes were analyzed for concordant expression in publicly available human prostate array datasets and a subset of resulting genes was analyzed by QRT-PCR.


RESULTS
Cross-referencing differentially expressed TRAMP genes to public human prostate array datasets revealed 66 genes with concordant expression in mouse and human PCa; 56 between metastases and normal and 10 between primary tumor and normal tissues. Of these 10 genes, two, Sox4 and Tubb2a, were validated by QRT-PCR. Our analysis also revealed various dysregulations in major biologic pathways in the TRAMP prostates.


CONCLUSIONS
We report a TRAMP microarray dataset of which a gene subset was validated by QRT-PCR with expression patterns consistent with previous gene-specific TRAMP studies. Concordance analysis between TRAMP and human PCa associated genes supports the utility of the model and suggests several novel molecular targets for preclinical therapy.
Haram
Kerstyn M
KM
Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA.
Peltier
Heidi J
HJ
Lu
Bin
B
Bhasin
Manoj
M
Otu
Hasan H
HH
Choy
Bob
B
Regan
Meredith
M
Libermann
Towia A
TA
Latham
Gary J
GJ
Sanda
Martin G
MG
Arredouani
Mohamed S
MS
D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology; D000818:Animals; D000951:Antigens, Neoplasm / Q000096:biosynthesis / Q000235:genetics*; D004195:Disease Models, Animal; D020869:Gene Expression Profiling / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic; D006609:High Mobility Group Proteins / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009376:Neoplasms, Hormone-Dependent / Q000235:genetics / Q000473:pathology; D020411:Oligonucleotide Array Sequence Analysis; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D012334:RNA, Neoplasm / Q000737:chemistry / Q000235:genetics; D053219:Receptors, Tumor Necrosis Factor, Member 25 / Q000096:biosynthesis* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D055751:SOXC Transcription Factors; D015534:Trans-Activators / Q000096:biosynthesis / Q000235:genetics; D015854:Up-Regulation
D000951:Antigens, Neoplasm; D006609:High Mobility Group Proteins; D012334:RNA, Neoplasm; D053219:Receptors, Tumor Necrosis Factor, Member 25; D055751:SOXC Transcription Factors; C489990:Sox4 protein, mouse; C506034:Tnfrsf25 protein, mouse; D015534:Trans-Activators